RAAB can assess diabetes and DR

Article

The Rapid Assessment of Avoidable Blindness (RAAB) framework can be used to assess diabetes and diabetic retinopathy (DR) but us costly and time consuming.

The Rapid Assessment of Avoidable Blindness (RAAB) framework can be used to assess diabetes and diabetic retinopathy (DR) but is costly and time consuming, according to a study recently published in the British Journal of Ophthalmology.

Dr Abdul Hamid Al Ghamdiet al.,, Hannah Kuper, Department of Clinical Research, London School of Hygiene & Tropical Medicine, 66 clusters of 50 people aged who underwent visual acuity measurements.

The DR was assessed via dilated fundus examination using a direct and indirect ophthalmoscope. Digital fundus photographs were graded using the Scottish DR grading system.

Of the 3052 patients examined, blindness prevalence was 2.6% and posterior segment diseases and cataract were identified as the leading cause of blindness. The agreement between clinical examination and reference standard was good for DR and STDR.

The RAAB can be used to evaluate diabetes and DR but it is time consuming, complex and costly.

The abstract can be found here.

.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.